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Summary Two male patients, one in his thirties and the other in his ﬁfties, were admitted to
different hospitals for congestive heart failure (CHF). In both patients, laboratory ﬁndings indi-
cated high plasma B-type natriuretic peptide (BNP) levels (266.0 and 902.7 pg/mL, respectively)
and echocardiography showed large left ventricular diastolic dimensions (LVDd) (67 and 73mm,
respectively) and low ejection fractions (EF) (26% and 18%, respectively). Coronary arteriog-
raphy revealed no organic stenosis in either patient. Following treatment, plasma BNP levels
decreased to below the limit of measurement (4 pg/mL) in both patients and echocardiogra-
phy revealed improved LVDd (61 and 52mm, respectively) and EF (41% and 45%, respectively).
Because these patients are related, genetic factors might have affected low plasma BNP levels.
Moreover, these results suggest that marked decrease in plasma BNP during follow up may be
an indicator of preserved neurohormonal and organ systems.
© 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
rIntroductionB-type natriuretic peptide (BNP) is a circulatory hormone
of cardiac origin and plays a cardioprotective role. It
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doi:10.1016/j.jccase.2011.10.006egulates both blood pressure and blood volume by diure-
is, natriuresis, vasodilation, and inhibition of aldosterone
ynthesis and renin secretion [1]. The diagnostic and prog-
ostic values of plasma BNP levels in congestive heart
ailure (CHF) are supported by previous studies [2,3]. We
resent the cases of 2 related patients of dilated car-
iomyopathy (DCM) with low plasma BNP levels, which
uggest interaction of genetic factors with plasma BNP
evels.
Published by Elsevier Ltd. All rights reserved.
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Figure 2 Time course of plasma B-type natriuretic peptide
(BNP) levels (), left ventricular end-diastolic dimension (LVDd)
() and ejection fraction (EF) (©) in patient 1. Plasma BNP
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ase 1
male patient in his thirties ﬁrst visited a hospital because
f dyspnea. He had no previous history of hypertension,
alvular heart disease, renal disease, or diabetes mellitus.
is blood pressure was 96/57mmHg and heart rate was
03 beats/min. Laboratory studies showed almost normal
ndings.
An electrocardiogram (ECG) showed normal sinus rhythm
ithout arrhythmia and the ﬁndings of left atrial overload,
igh R wave in leads V4 to V6, and negative T wave in
eads II, III, aVF, and V2 to V5. Echocardiography showed
nlargement and diffuse hypokinesis of the left ventri-
le (LV): LV end-diastolic dimension (LVDd) was 67mm and
jection fraction (EF) was 26%. After 3weeks of acute
eat failure treatment, plasma BNP level was measured
or the ﬁrst time using commercially available speciﬁc-
nzyme immunoassay kits (Shionogi, Florham Park, NJ, USA
4] and TOSOH, Tokyo, Japan), was found to be 266.0 pg/mL.
hen, he underwent cardiac catheterization. Hemodynamic
ata showed a cardiac output of 5.2 Lmin−1, a cardiac
ndex of 2.8 Lmin−1 m−2, a pulmonary artery wedge pres-
ure of 25mmHg, and LV end-diastolic pressure of 34mmHg.
oronary arteriogram showed no organic stenosis. Left ven-
riculography showed diffuse hypokinesis of LV wall (EF of
5%).
After discharge from the hospital, the patient was
eferred to the outpatient department of our hospital. Here,
is plasma BNP level was determined to be 60.8 pg/mL.
hest X-ray ﬁlm showed a cardio-thoracic ratio of 48%. Addi-
ionally, echocardiography showed LVDd of 71mm and EF of
1% (Fig. 1, left).
During the follow-up with angiotensin-converting enzyme
nhibitor (enalapril 2.5mg/day), diuretics (furosemide
0mg and spironolactone 25mg/day), and a beta-blocker
carvedilol 5mg/day), both the LV wall motion by echocar-
iography and plasma BNP levels measured by the same kit
radually improved. Fifteen months later, echocardiography
evealed an LVDd of 61mm, and an EF of 41% (Fig. 1, right
nd Fig. 2), and plasma BNP levels decreased to below the
ower limit of measurement (4 pg/mL) (Fig. 2).
igure 1 M-mode echocardiograms of left ventricle (LV) in
atient 1 at the ﬁrst visit as outpatient (left) and 12months
ater (right). LV end-diastolic dimension (LVDd) decreased from
1 to 61mm and ejection fraction increased from 21% to 41%.
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6evels markedly decreased and fell below the lower limit of
pg/mL. LVDd decreased and EF increased.
ase 2
n uncle of case 1 in his ﬁfties visited our hospital because
f cough and dyspnea that had persisted for 2weeks. He
ad no signiﬁcant previous history either. His blood pressure
as 133/97mmHg, pulse rate was 106 beats/min. Auscul-
ation of the heart sound showed gallop rhythm. Blood
amples showed normal hemogram, cardiac enzymes lev-
ls, and renal function. Plasma BNP level was 902.7 pg/mL.
n ECG showed sinus rhythm with high R wave in leads V5
nd V6 and negative T wave in leads I, II, aVL, V5, and
6. Chest radiograph showed cardiomegaly (cardiothoracic
atio 67%) without pulmonary congestion. Echocardiog-
aphy showed enlarged and hypokinetic LV (Dd: 73mm;
F: 18%) (Fig. 3, left). In cardiac catheterization, coro-
ary angiography showed no coronary stenosis. After the
atient was discharged from the hospital, he was treated
t our outpatient department with an angiotensin recep-
or blocker (losartan 25mg/day) and diuretics (furosemide
0mg/day and spironolactone 25mg/day). During follow-
p, the wall motion gradually improved (18months later,
VDd was 52mm and EF was 45%) (Fig. 3, right). Plasma BNP
evel decreased to below the lower limit of measurement
4 pg/mL) (Fig. 4).
iscussion
he 2 related patients followed similar clinical courses. They
rst visited hospitals due to dyspnea and were treated for
HF. Laboratory ﬁndings revealed high plasma BNP levels,
nlarged and severe hypokinetic LV, and normal coronary
rteries, and they were diagnosed with DCM. Following
reatment in the outpatient department, LV wall motion
mproved and plasma BNP levels decreased to below the
ower limit of measurement (4 pg/mL) in both patients.
In CHF patients, plasma BNP levels average
75± 450 pg/mL [5] and in acute settings may become
Marked decrease in BNP levels in 2 related patients with reversib
Figure 3 B-mode echocardiograms of LV in patient 2 on
admission (upper) and 18months later (lower). Left ventricu-
F
B
B
c
d
f
[
B
t
[
c
O
a
p
f
s
u
s
h
t
m
d
p
c
n
s
m
f
a
m
i
3lar end-diastolic dimension decreased from 73 to 52mm and
ejection fraction increased from 18% to 45%.
as high as 1076± 138 pg/mL [2]. In normal males between
45 and 64 years of age, plasma BNP levels from 5th to 95th
percentiles range from 6 to 146 pg/mL [6]. In this case
report, although plasma BNP level was not measured in
acute phase in case 1, plasma BNP levels were lower in
acute heart failure in case 2 and during follow-up in both
patients.
Figure 4 Time course of plasma B-type natriuretic peptide
levels (BNP; ), left ventricular end-diastolic dimension (LVDd;
) and ejection fraction (EF; ©) in patient 2. Three parameters
similarly changed as patient 1. Plasma BNP levels decreased
markedly to below the lower limit of 4 pg/mL.
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actors affecting plasma BNP levels
NP levels are known to be inﬂuenced by various factors.
NP levels increase signiﬁcantly with age and are signiﬁ-
antly higher among women [6]. Moreover, low heart rate,
iabetes mellitus, valvular heart disease, impaired renal
unction, and high albumin might also affect BNP levels
7]. There have been also reports about the mechanisms of
NP decrease. BNP is eliminated from blood by the kidney,
he natriuretic peptidase clearance receptor, and peptidases
8]. Thus, higher renal function or abundant natriuretic
learance receptors or peptidases may decrease plasma BNP.
besity is related with low plasma BNP, possibly due to
bundant natriuretic peptide clearance receptors in adi-
ose tissue and reduced secretion of natriuretic peptides
rom diminished myocardial hormone release or impaired
ynthesis [9]. Genetic factors may also inﬂuence the natri-
retic peptide system. Nakayama et al. found mutations in
tructure of the natriuretic peptide receptor genes in some
ypertensive patients, whose plasma BNP levels were higher
han those who had normal structure genes [10]. Although
ore familial history and genetic factors are to be eluci-
ated, this case report suggests some relationship between
lasma BNP levels and a genetic factor.
Heart failure is a multi-system disease involving not only
ardiovascular hemodynamic dysfunction, but also altered
eurohormonal reﬂexes and impairment of other organs,
uch as the kidney or skeletal muscle [11]. Koglin et al. [12]
easured plasma BNP levels in chronic CHF patients and
ound a signiﬁcant correlation between plasma BNP levels
nd the heart failure survival score. They reported that BNP
ight provide information on multiple constituents involved
n the pathophysiology of CHF.
Maeda et al. [4] measured plasma BNP levels before and
months after optimized treatment and found that sus-
ained high BNP plasma levels following additional standard
reatment was an independent risk factor for mortality in
atients with CHF despite improvement in LVEF and symp-
oms.
In the present case report, a marked decrease in plasma
NP levels and improvement in EF was observed within
.5 years, which suggests that neurohormonal and organ sys-
ems were not severely deteriorated in both patients.
These 2 cases suggest the association of a genetic factor
ith plasma BNP level and demonstrate the signiﬁcance of
ts measurement when estimating the prognosis of patients
ith CHF.
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